Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Norbert Heinrich

Has grant

Scientific Lead TB

LMU University Hospital

Germany

Research Interests

Explore related searches

Professors in Germany

Recent Grants

Grant: Close

EX-DR TB: ELIMINATION OF EXTENSIVE DRUG RESISTANCE THROUGH BETTER DIAGNOSTICS AND REGIMENS FOR TB

Open Date: 2025-07-01

Close Date:

Grant: Close

MICA: Radio+ TB trial development: Determining the optimal regimen for bacteriologically negative, radiographically apparent TB diagnosed usingnewtest

Open Date: 2021-02-01

Close Date: 2022-07-30

Grant: Close

Early Risk Assessment in TB Contacts by new diagnoStic tEsts

Open Date: 2020-05-01

Close Date: 2024-04-30

Grant: Close

Rapid and accurate diagnosis of paediatric TB

Open Date: 2018-02-01

Close Date: 2023-01-31

Grant: Close

PanACEA 2, a drug development programme to shorten and simplify TB treatment

Open Date: 2017-02-01

Close Date:

Articles (20)

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (8)

Wilber Sabiiti

University of St. Andrews

UNITED KINGDOM

View details

Young Lag Cho

Chief Development Officer

SOUTH KOREA

View details

Nestani Tukvadze

Senior Scientist

Swiss Tropical and Public Health Institute

SWITZERLAND

View details

Sean Wasserman

Clinical Professor of Infectious Diseases

St George’s, University of London

UNITED KINGDOM

View details

Kathrin Held

University Hospital, LMU Munich

GERMANY

View details

Patrick Phillips

Associate Professor

University of California, San Francisco

UNITED STATES

View details

Laurence Borand

Associate Professor of Medicine

Johns Hopkins University

UNITED STATES

View details

Derek James Sloan

University of St. Andrews

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Norbert Heinrich

Research Interests

Explore related searches

Recent Grants

Articles (20)

When are Uncontrolled Trials in TB Scientifically and Ethically Justified: Borrowing Wisdom From Early AIDS Clinical Trials

Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB

Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials

Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043–02)

Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial

Body Mass Index Trajectories and Association With Tuberculosis Risk in a Cohort of Household Contacts in Southern Africa

Prediction models for Mtb infection among adolescent and adult household contacts in high tuberculosis incidence settings

Diagnostic accuracy of the WHO tuberculosis treatment decision algorithms for children with presumptive tuberculosis: An individual participant data meta-analysis

Evaluating the diagnostic accuracy of WHO-recommended treatment decision algorithms for childhood tuberculosis using an individual person dataset: a study protocol

DRTB-HDT: a randomized controlled trial of two adjunctive host-directed therapies in rifampin-resistant tuberculosis

Corrigendum to Candidate anti-tuberculosis medicines and regimens under clinical evaluation.

Shaping opportunities for future clinical trials in tuberculosis.

[Treatment of tuberculosis in adults].

First-in-human study of the benzothiazinone and DprE1 inhibitor BTZ-043, a novel drug candidate for the treatment of Tuberculosis.

Implications of reference equations for interpretation of spirometry in three African countries: a cross-sectional study.

Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial.

endTB-Q results in the face of rising bedaquiline resistance.

Neuromyelitis optica causing vision loss during TB treatment with sutezolid: evidence of aberrant immunity following infection.

Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043.

The clinical-stage drug BTZ-043 accumulates in murine tuberculosis lesions and efficiently acts against Mycobacterium tuberculosis.

Collaborators (8)

Wilber Sabiiti

Young Lag Cho

Nestani Tukvadze

Sean Wasserman

Kathrin Held

Patrick Phillips

Laurence Borand

Derek James Sloan

Make your next move.